162 related articles for article (PubMed ID: 26024445)
1. Structural dynamics of the cereblon ligand binding domain.
Hartmann MD; Boichenko I; Coles M; Lupas AN; Hernandez Alvarez B
PLoS One; 2015; 10(5):e0128342. PubMed ID: 26024445
[TBL] [Abstract][Full Text] [Related]
2. The thalidomide-binding domain of cereblon defines the CULT domain family and is a new member of the β-tent fold.
Lupas AN; Zhu H; Korycinski M
PLoS Comput Biol; 2015 Jan; 11(1):e1004023. PubMed ID: 25569776
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide mimics uridine binding to an aromatic cage in cereblon.
Hartmann MD; Boichenko I; Coles M; Zanini F; Lupas AN; Hernandez Alvarez B
J Struct Biol; 2014 Dec; 188(3):225-32. PubMed ID: 25448889
[TBL] [Abstract][Full Text] [Related]
4. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component.
Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA
Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444
[TBL] [Abstract][Full Text] [Related]
5. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate.
Matyskiela ME; Couto S; Zheng X; Lu G; Hui J; Stamp K; Drew C; Ren Y; Wang M; Carpenter A; Lee CW; Clayton T; Fang W; Lu CC; Riley M; Abdubek P; Blease K; Hartke J; Kumar G; Vessey R; Rolfe M; Hamann LG; Chamberlain PP
Nat Chem Biol; 2018 Oct; 14(10):981-987. PubMed ID: 30190590
[TBL] [Abstract][Full Text] [Related]
6. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
7. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of thalidomide enantiomer binding to cereblon.
Mori T; Ito T; Liu S; Ando H; Sakamoto S; Yamaguchi Y; Tokunaga E; Shibata N; Handa H; Hakoshima T
Sci Rep; 2018 Jan; 8(1):1294. PubMed ID: 29358579
[TBL] [Abstract][Full Text] [Related]
9. [Thalidomide teratogenicity and its direct target identification].
Ito T; Ando H; Handa H
Nihon Rinsho; 2015 Jan; 73(1):143-8. PubMed ID: 25626320
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode.
Shevalev R; Bischof L; Sapegin A; Bunev A; Olga G; Kantin G; Kalinin S; Hartmann MD
Eur J Med Chem; 2024 Apr; 270():116328. PubMed ID: 38552426
[TBL] [Abstract][Full Text] [Related]
11. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).
Schiedel M; Herp D; Hammelmann S; Swyter S; Lehotzky A; Robaa D; Oláh J; Ovádi J; Sippl W; Jung M
J Med Chem; 2018 Jan; 61(2):482-491. PubMed ID: 28379698
[TBL] [Abstract][Full Text] [Related]
12. [Recent topics in IMiDs and cereblon].
Ito T; Handa H
Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
[TBL] [Abstract][Full Text] [Related]
13. Genomic and in silico analyses of CRBN gene and thalidomide embryopathy in humans.
Vianna FS; Kowalski TW; Tovo-Rodrigues L; Tagliani-Ribeiro A; Godoy BA; Fraga LR; Sanseverino MT; Hutz MH; Schuler-Faccini L
Reprod Toxicol; 2016 Dec; 66():99-106. PubMed ID: 27751757
[TBL] [Abstract][Full Text] [Related]
14. Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production.
Millrine D; Tei M; Gemechu Y; Kishimoto T
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10625-30. PubMed ID: 27601648
[TBL] [Abstract][Full Text] [Related]
15. Cereblon is recruited to aggresome and shows cytoprotective effect against ubiquitin-proteasome system dysfunction.
Sawamura N; Wakabayashi S; Matsumoto K; Yamada H; Asahi T
Biochem Biophys Res Commun; 2015 Sep; 464(4):1054-1059. PubMed ID: 26188093
[TBL] [Abstract][Full Text] [Related]
16. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
17. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Winter GE; Buckley DL; Paulk J; Roberts JM; Souza A; Dhe-Paganon S; Bradner JE
Science; 2015 Jun; 348(6241):1376-81. PubMed ID: 25999370
[TBL] [Abstract][Full Text] [Related]
18. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the mystery of thalidomide teratogenicity.
Ito T; Handa H
Congenit Anom (Kyoto); 2012 Mar; 52(1):1-7. PubMed ID: 22348778
[TBL] [Abstract][Full Text] [Related]
20. Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?
Ley AM; Chau CH; Figg WD
Cancer Biol Ther; 2015; 16(1):19-20. PubMed ID: 25692618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
